Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management

Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study

(2022) Gabriel Bsteh et al.   EUROPEAN JOURNAL OF NEUROLOGY

B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications

(2022) Marco Iannetta et al.   Frontiers in Immunology

Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

(2021) Michael Guger et al.   JOURNAL OF NEUROLOGY

Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy

(2021) Arpan Patel et al.   JAMA Neurology

Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

(2021) Javier Riancho et al.   Frontiers in Immunology

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience

(2021) Guerrieri S. et al.   JOURNAL OF NEUROLOGY

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

(2021) Stephen L Hauser et al.   NEUROLOGY

Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis

(2021) Giulio Disanto et al.   JAMA Neurology

Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab

(2021) Livnat Brill et al.   JAMA Neurology

Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia

(2021) Mohammed Al Jumah et al.   Multiple Sclerosis and Related Disorders

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

(2021) Leoni Rolfes et al.   Neurology-Neuroimmunology & Neuroinflammation

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

(2021) Matthias B Moor et al.   Lancet Rheumatology

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

(2021) Anat Achiron et al.   JOURNAL OF NEUROIMMUNOLOGY

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

(2021) Alasdair J Coles et al.   Multiple Sclerosis Journal

Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis

(2021) Frederik Novak et al.   Multiple Sclerosis and Related Disorders

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses

(2021) Jose M. Serra López-Matencio et al.   Frontiers in Neurology

Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis

(2021) Lutz Achtnichts et al.   Vaccines

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients

(2020) Peter Alping et al.   ANNALS OF NEUROLOGY

Pharmacodynamics of natalizumab extended interval dosing in MS

(2020) Lana Zhovtis Ryerson et al.   Neurology-Neuroimmunology & Neuroinflammation

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

(2020) Anna He et al.   LANCET NEUROLOGY

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis

(2020) Edward Fox et al.   Multiple Sclerosis Journal

Alemtuzumab: Rare serious adverse events of a high-efficacy drug

(2020) Hans-Peter Hartung et al.   Multiple Sclerosis Journal

Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder

(2020) Andrea Ines Ciplea et al.   Neurology-Neuroimmunology & Neuroinflammation

Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases

(2020) Sara C. LaHue et al.   Neurology-Neuroimmunology & Neuroinflammation

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

(2020) Tjalf Ziemssen et al.   CNS DRUGS

Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

(2020) Stephen L. Hauser et al.   NEUROLOGY

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study

(2020) Amit Bar-Or et al.   NEUROLOGY

Ofatumumab versus Teriflunomide in Multiple Sclerosis

(2020) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years

(2020) Jiwon Oh et al.   Multiple Sclerosis and Related Disorders

Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry

(2020) Michael Guger et al.   Frontiers in Neurology

Ocrelizumab shorter infusion

(2020) Hans-Peter Hartung   Neurology-Neuroimmunology & Neuroinflammation

Mitigating alemtuzumab-associated autoimmunity in MS

(2020) Ethan Meltzer et al.   Neurology-Neuroimmunology & Neuroinflammation

Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review

(2020) Huah Shin Ng et al.   Expert Opinion On Drug Safety

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing

(2020) Ih Chang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

(2020) Imtiaz A Samjoo et al.   Journal of Comparative Effectiveness Research

Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing

(2019) John F. Foley et al.   Multiple Sclerosis and Related Disorders

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

(2019) Adam Cuker et al.   Multiple Sclerosis Journal

Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing–Remitting Multiple Sclerosis Patients

(2019) Jillian K. Chan et al.   JOURNAL OF NEURO-OPHTHALMOLOGY

Highly active multiple sclerosis: An update

(2019) Cindy Díaz et al.   Multiple Sclerosis and Related Disorders

Considerations for the Design of Antibody-Based Therapeutics

(2019) Dennis R. Goulet et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab

(2019) J William L Brown et al.   Multiple Sclerosis Journal

Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life

(2019) Kevin O. Saunders   Frontiers in Immunology

Emerging safety issues in alemtuzumab-treated MS patients

(2019) Joep Killestein et al.   Multiple Sclerosis Journal

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

(2019) Marinella Clerico et al.   Neurotherapeutics

Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies

(2019) Danielle J. Smalls et al.   PHARMACOTHERAPY

Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions

(2019) Kristen M. Krysko et al.   Neurology-Neuroimmunology & Neuroinflammation

B-cell Therapy for Multiple Sclerosis: Entering an era

(2018) Ariele L. Greenfield et al.   ANNALS OF NEUROLOGY

Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy

(2018) H. K. Olberg et al.   EUROPEAN JOURNAL OF NEUROLOGY

‘No evidence of disease activity’ - is it an appropriate surrogate in multiple sclerosis?

(2018) H. Hegen et al.   EUROPEAN JOURNAL OF NEUROLOGY

Alemtuzumab for the treatment of multiple sclerosis

(2018) Jennifer R. Evan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis

(2018) Antonio Riccardo Buonomo et al.   Expert Opinion On Drug Safety

Ublituximab for the treatment of CD20 positive B-cell malignancies

(2018) Hani M. Babiker et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

(2018) E. C. Tallantyre et al.   JOURNAL OF NEUROLOGY

Multiple sclerosis

(2018) Alan J Thompson et al.   LANCET

Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients

(2018) Yasuo Oshima et al.   Multiple Sclerosis Journal

A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab

(2018) Irene M Vavasour et al.   Multiple Sclerosis Journal

Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab

(2018) Benoit Meunier et al.   Multiple Sclerosis Journal

Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis

(2018) Thomas Wehrum et al.   NEUROLOGY

Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab

(2018) Mika Saarela et al.   NEUROLOGY

Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance

(2018) Paolo A. Muraro et al.   NEUROLOGY

Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab

(2018) Sherry Masoud et al.   RHEUMATOLOGY

Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients

(2018) Yasuo Oshima et al.   Multiple Sclerosis Journal

A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab

(2018) Irene M Vavasour et al.   Multiple Sclerosis Journal

Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab

(2018) Benoit Meunier et al.   Multiple Sclerosis Journal

Severe neutropenia after rituximab-treatment of multiple sclerosis

(2018) Eero Rissanen et al.   Multiple Sclerosis and Related Disorders

Efficacy and safety of natalizumab extended interval dosing

(2018) Bassem I. Yamout et al.   Multiple Sclerosis and Related Disorders

Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis

(2018) L.J.W. Canham et al.   Multiple Sclerosis and Related Disorders

Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies

(2018) Christoph Metze et al.   CNS Neuroscience & Therapeutics

Infusion-related reactions to rituximab: frequency, mechanisms and predictors

(2018) Franciane Paul et al.   Expert Review of Clinical Immunology

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

(2018) Sibyl Wray et al.   Multiple Sclerosis Journal

Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria

(2018) Gabriel Bsteh et al.   Multiple Sclerosis Journal

Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment

(2018) Jonas Graf et al.   Multiple Sclerosis Journal

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients

(2018) Stefan Gingele et al.   Cells

Management of Demyelinating Disorders in Pregnancy

(2018) Tamara B. Kaplan   NEUROLOGIC CLINICS

Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis

(2017) Kumar Kandadi Muralidharan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence

(2017) Omid Mirmosayyeb et al.   Journal of Research in Medical Sciences

Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy

(2017) Aiden Haghikia et al.   LANCET NEUROLOGY

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

(2017) Pei-Ran Ho et al.   LANCET NEUROLOGY

Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab

(2017) Marinella Clerico et al.   Multiple Sclerosis Journal

Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome

(2017) Wallace J Brownlee et al.   Multiple Sclerosis Journal

Rituximab treatment of myasthenia gravis: A systematic review

(2017) Rup Tandan et al.   MUSCLE & NERVE

Alemtuzumab CARE-MS I 5-year follow-up

(2017) Eva Havrdova et al.   NEUROLOGY

Alemtuzumab CARE-MS II 5-year follow-up

(2017) Alasdair J. Coles et al.   NEUROLOGY

Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab

(2017) Joshua Barton et al.   NEUROLOGY

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis

(2017) Jeffrey M. Gelfand et al.   Neurotherapeutics

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low level of Rituximab in human breast milk in a patient treated during lactation

(2017) Yngvill Bragnes et al.   RHEUMATOLOGY

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

(2017) David Baker et al.   JAMA Neurology

Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab

(2017) Marinella Clerico et al.   Multiple Sclerosis Journal

Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome

(2017) Wallace J Brownlee et al.   Multiple Sclerosis Journal

Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis

(2017) Saša Šega-Jazbec et al.   Multiple Sclerosis and Related Disorders

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis

(2017) Cristina Guarnera et al.   Therapeutics and Clinical Risk Management

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

(2017) Eva Havrdova et al.   Therapeutics and Clinical Risk Management

Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response

(2017) Mario Rotondi et al.   Frontiers in Endocrinology

Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study

(2016) Susan Friend et al.   BMC Neurology

Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial

(2016) Jeff P. Sharman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis

(2016) JL Orthmann-Murphy et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

(2016) Thomas Berger et al.   CNS DRUGS

Targeting B cells in treatment of autoimmunity

(2016) S Elizabeth Franks et al.   CURRENT OPINION IN IMMUNOLOGY

Disease activity return after natalizumab cessation in multiple sclerosis

(2016) Maria Rasenack et al.   Expert Review of Neurotherapeutics

Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis

(2016) María Rosario Blasco et al.   JOURNAL OF NEUROLOGY

Extended interval dosing of natalizumab in multiple sclerosis

(2016) L Zhovtis Ryerson et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

(2016) MD Willis et al.   Multiple Sclerosis Journal

Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS

(2016) Steffen Pfeuffer et al.   NEUROLOGY

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

(2016) Douglas L. Arnold et al.   NEUROLOGY

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

Disease activity return after natalizumab cessation in multiple sclerosis

(2016) Maria Rasenack et al.   Expert Review of Neurotherapeutics

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

(2016) MD Willis et al.   Multiple Sclerosis Journal

Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management

(2015) Moeber Mahzari et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Classification, diagnosis, and differential diagnosis of multiple sclerosis

(2015) Ilana Katz Sand   CURRENT OPINION IN NEUROLOGY

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases

(2015) Daniela Rau et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs

(2014) E. Portaccio et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis

(2014) Michael Kaufman et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

The global burden of listeriosis: a systematic review and meta-analysis

(2014) Charline Maertens de Noordhout et al.   LANCET INFECTIOUS DISEASES

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis

(2014) Hans-Peter Hartung et al.   Multiple Sclerosis Journal

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity

(2014) O. Kousin-Ezewu et al.   NEUROLOGY

Natalizumab Use During the Third Trimester of Pregnancy

(2014) Aiden Haghikia et al.   JAMA Neurology

FDA: Increased HBV Reactivation Risk With Ofatumumab or Rituximab

(2013) Mike Mitka   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis

(2013) X. Zhang et al.   JOURNAL OF IMMUNOLOGY

Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion

(2013) M Le Garff-Tavernier et al.   LEUKEMIA

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

(2013) Christian Klein et al.   mAbs

Immune competence after alemtuzumab treatment of multiple sclerosis

(2013) C. L. McCarthy et al.   NEUROLOGY

Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation

(2013) J. L. Jones et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rituximab for the treatment of rheumatoid arthritis: an update

(2013) Chi Chiu Mok   Drug Design Development and Therapy

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab

(2012) T. Button et al.   Multiple Sclerosis Journal

Humoral immune response to influenza vaccine in natalizumab-treated MS patients

(2012) Mattias Vågberg et al.   NEUROLOGICAL RESEARCH

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

(2011) A. Cuker et al.   BLOOD

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

(2011) Grant A Hill-Cawthorne et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

(2011) J Theodore Phillips et al.   Multiple Sclerosis Journal

Immune reconstitution inflammatory syndrome in natalizumab-associated PML

(2011) I. L. Tan et al.   NEUROLOGY

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

(2011) M. Cossburn et al.   NEUROLOGY

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

Pregnancy outcomes after maternal exposure to rituximab

(2010) E. F. Chakravarty et al.   BLOOD

CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment

(2010) Giovanni Frisullo et al.   Multiple Sclerosis Journal

The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases

(2010) Valeria Bruno et al.   NEUROLOGICAL SCIENCES

Hepatitis B Reactivation and Rituximab in the Oncology Practice

(2010) J. Villadolid et al.   ONCOLOGIST

Developmental Immunotoxicology Assessment of Rituximab in Cynomolgus Monkeys

(2010) Anu Vaidyanathan et al.   TOXICOLOGICAL SCIENCES

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

(2009) Clifton O. Bingham et al.   ARTHRITIS AND RHEUMATISM

Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor

(2009) Nancy G. Wehner et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

Effects of natalizumab, an α4 integrin inhibitor, on fertility in male and female guinea pigs

(2009) Nancy G. Wehner et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an α4 integrin inhibitor

(2009) Nancy G. Wehner et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model

(2009) Yanping Hu et al.   IMMUNOLOGY

Receptor-mediated uptake and transport of macromolecules in the human placenta

(2009) Henning Schneider et al.   INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY

B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

(2009) Sara A. J. Thompson et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

(2009) B. O. Khatri et al.   NEUROLOGY

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development

(2008) D. T. Klink et al.   Clinical & Developmental Immunology

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE